摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

异丁酸肼 | 3619-17-8

中文名称
异丁酸肼
中文别名
异丁酰肼
英文名称
isobutyric acid hydrazide
英文别名
isobutyrohydrazide;2-methylpropanehydrazide;isobutyryl hydrazine;isobutyryl hydrazide
异丁酸肼化学式
CAS
3619-17-8
化学式
C4H10N2O
mdl
MFCD00025122
分子量
102.136
InChiKey
PLNNJQXIITYYTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    97 °C
  • 沸点:
    238.6±9.0 °C(Predicted)
  • 密度:
    0.976±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇
  • 稳定性/保质期:
    在常温常压下,该物质是稳定的。

计算性质

  • 辛醇/水分配系数(LogP):
    -0.6
  • 重原子数:
    7
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    55.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 安全说明:
    S26,S36/37/39
  • 海关编码:
    2928000090
  • 危险品标志:
    Xi
  • 危险类别码:
    R20/21/22
  • WGK Germany:
    3
  • 包装等级:
    II
  • 危险类别:
    4.1
  • 危险性防范说明:
    P210,P240,P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P370+P378,P403+P233,P501
  • 危险品运输编号:
    1325
  • 危险性描述:
    H228,H302,H315,H319,H335
  • 储存条件:
    请将药物存放在避光、通风且干燥的地方,并密封保存。

SDS

SDS:88f7587b28d4b4d1b926921c6da7b148
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Isobutyric acid hydrazide
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Isobutyric acid hydrazide
CAS number: 3619-17-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H10N2O
Molecular weight: 102.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

异丁酰肼可用作医药合成中间体。其具体应用包括:

  1. 制备3-异丙基-4-氨基-1,2,4-三唑啉-5-酮,步骤如下:

    • 在正丁醇溶剂中,在反应温度为50~150℃下,将异丁酸和水合肼进行反应,生成异丁酰肼。
    • 在反应温度为0~60℃下,将上一步合成的异丁酰肼反应液与光气或固光以及正丁醇作为溶剂进行反应,生成2-异丁基肼基甲酸丁酯。
    • 在碱溶液中,在反应温度为80~120℃下,将步骤二中的产物与水合肼进行反应,生成3-异丙基-4-氨基-1,2,4-三唑啉-5-酮和正丁醇。该方法全程使用单一的正丁醇作为溶剂,中间过程不分离,具有操作简单、反应速度快、“三废”量少;正丁醇可反复利用;合成收率高达85%等优点。
  2. 制备一类新的吲哚衍生物。以吲哚-3-甲醛的衍生物和异丁酰肼为原料,通过化学反应引入抗癌活性基团如-OCH3、-C=N-NH-C=O等,到吲哚的适当位置,得到一系列多官能团的吲哚类化合物。该工艺操作简便、条件温和、产率高,并且这些化合物具有良好的生物活性,可用于治疗肿瘤,在药学领域内有着广泛的应用前景。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    异丁酰胺 Isobutyramide 563-83-7 C4H9NO 87.1216
    甲基丙烯酰肼 methacryloyl hydrazide 2388-01-4 C4H8N2O 100.12
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— N,N'-Di-iso-butyrylhydrazin 1530-53-6 C8H16N2O2 172.227

反应信息

  • 作为反应物:
    描述:
    异丁酸肼正丁基锂 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 2.0h, 生成 异丁醛
    参考文献:
    名称:
    酰肼和与正丁基锂的反应
    摘要:
    当用3当量的正丁基锂处理时,芳族酰肼以良好的收率得到吲哚-3(2 H)-酮;在相同条件下,脂族和杂环酰肼可提供相应的醛。
    DOI:
    10.1039/c39820000450
  • 作为产物:
    描述:
    参考文献:
    名称:
    一种1,3,4-噻二唑衍生物的合成方法
    摘要:
    本发明公开了一种1,3,4‑噻二唑衍生物的合成方法,包括:(1)以水合肼为原料,在催化剂作用下与酸进行反应得酰肼化合物Ⅰ;(2)以氯甲酸烷基酯、硫氰酸盐在溶剂条件下反应,得到异硫氰酸酯化合物Ⅱ;(3)在异硫氰酸酯化合物Ⅱ的反应体系中,加含有化合物Ⅰ的溶液,反应得含有化合物Ⅲ的溶液;(4)化合物Ⅲ的溶液经脱水、中和、水洗,得化合物Ⅳ;(5)化合物Ⅳ在缚酸剂和溶剂条件下加入卤代烷或硫酸二酯进行反应,得化合物Ⅴ;(6)化合物Ⅴ与伯胺进行胺化反应得1,3,4‑噻二唑衍生物Ⅵ。本发明制备方法具备绿色无污染、操作简便、收率较高、反应条件温和等优点。
    公开号:
    CN108794427B
  • 作为试剂:
    描述:
    六甲基磷酰三胺2,3-二氯喹喔啉异丁酸肼 作用下, 反应 3.0h, 以0.2 g的产率得到3-(dimethylamino)quinoxalin-2(1H)-one
    参考文献:
    名称:
    Sastry, Reddy C V; Krishnan, V S H; Narayan, G K A S S, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 10, p. 936 - 940
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • THIAZOLYL-DIHYDRO-CHINAZOLINE
    申请人:Brandl Trixi
    公开号:US20070238746A1
    公开(公告)日:2007-10-11
    Disclosed are compounds of general formula (I), wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.
    揭示了一般式(I)的化合物, 其中,基团A,R1,R2,Ra和Rb具有权利要求和说明中给定的含义,其互变异构体,拉克酸盐,对映体,非对映体和它们的混合物,以及可选择的药理学上可接受的酸加盐,溶剂合物和水合物,以及制备这些噻唑基-二氢喹唑啉并将其用作药物组合物的方法。
  • THIAZOLYL-DIHYDRO-INDAZOLE
    申请人:Maier Udo
    公开号:US20070259855A1
    公开(公告)日:2007-11-08
    Disclosed are compounds of general formula (I), wherein the groups R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.
    揭示了一般式(I)的化合物, 其中基团R1、R2、Ra和Rb具有权利要求和说明中给定的含义,其互变异构体、消旋体、对映体、非对映异构体及其混合物,以及可选择的药理学上可接受的酸加盐、溶剂化合物和水合物,以及制备这些噻唑基二氢吲唑烷并将其用作药物组合物的方法。
  • Enantioselective N-Heterocyclic Carbene Catalyzed Synthesis of Functionalized Indenes
    作者:Changhe Zhang、David W. Lupton
    DOI:10.1021/acs.orglett.7b01981
    日期:2017.9.1
    An enantioselective NHC (N-heterocyclic carbene) catalyzed synthesis of indenes from bifunctional α,β-unsaturated acyl fluorides and TMS enol ethers has been discovered. The reaction has broad generality (31 examples) and proceeds with high levels of enantioselectivity (most >92:8 er). Mechanistically the reaction likely occurs via a Michael/β-lactonization/decarboxylation sequence. Derivatization
    已发现对映选择性NHC(N-杂环卡宾)催化双官能α,β-不饱和酰基氟和TMS烯醇醚的合成。该反应具有广泛的通用性(31个实例),并且以高水平的对映选择性(大多数> 92:8 er)进行。从机理上讲,该反应可能通过迈克尔/β-内酯化/脱羧序列发生。讨论了衍生化研究及其局限性。
  • Synthesis and in vitro leishmanicidal activity of some hydrazides and their analogues
    作者:Khalid Mohammad Khan、Maimona Rasheed、Zia Ullah、Safdar Hayat、Farhana Kaukab、M.Iqbal Choudhary、Atta ur-Rahman、Shahnaz Perveen
    DOI:10.1016/s0968-0896(02)00611-9
    日期:2003.4
    Twenty-one hydrazides were synthesized by treating different esters with hydrazine hydrate. Substituted hydrazides were obtained by treating hydrazides with alkyl/aryl/acyl halides. Some of these compounds exhibit potential in vitro leishmanicidal activity. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
    通过用水合肼处理不同的酯来合成二十一个酰肼。通过用烷基/芳基/酰基卤化物处理酰肼得到取代的酰肼。这些化合物中的某些表现出潜在的体外杀菌作用。所有合成化合物的结构通过光谱分析确认。
  • INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
    申请人:Dumas Jacques
    公开号:US20120046290A1
    公开(公告)日:2012-02-23
    This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    本发明涉及一组芳香脲在治疗细胞因子介导的疾病(除癌症外)和蛋白水解酶介导的疾病(除癌症外)中的用途,以及用于此类治疗的药物组合物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物